MAP2K7 and breast cancer: To validate the effects of MAP2K7 loss in ER+ breast cancer, we engineered multiple MAP2K7 CRISPR/Cas9 knockouts in MCF-7 and T-47D cells (MKK7_1 and MKK7_3; Fig. 2A, C) and empty vector pLenti cells.